一、权益分派预案情况 根据公司 2025 年 8 月 26 日披露的 2025 年半年度报告（财务报告未经审计）， 截至 2025 年 6 月 30 日，上市公司合并报表未分配利润为 66,361,701.77 元，母 公司未分配利润为 65,250,061.81 元。 证券代码：832278 证券简称：鹿得医疗 公告编号：2025-091 江苏鹿得医疗电子股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 江苏鹿得医疗电子股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日 召开第四届董事会第十次会议，审议通过《2025 年半年度权益分派预案的议案》， 现将相关事宜公告如下： 二、最近三年现金分红情况 公司合并资产负债表、母公司资产负债表中本年末未分配利润为正值且报告 期内盈利，最近三年已分配及拟分配的现金红利总额（包括中期分配的现金红利 金额 8,077,671.34 元）共计 91,837,671.34 元，占最近三年年均归属于上市公司股 东的净利润比例为 292.77%， ...

中国经济网北京8月14日讯 鹿得医疗(832278.BJ)昨日披露持股5%以上股东、实际控制人、董事、高级 管理人员拟减持股份的预披露公告。 因个人资金需求，鹿得医疗持股5%以上股东、实际控制人、董事项国强拟自公告披露之日起30个交易 日后的三个月内通过集中竞价或大宗交易减持鹿得医疗2,480,000股，计划减持数量占总股本比例 1.4091%。 因个人资金需求，鹿得医疗董事、高级管理人员朱文军拟自公告披露之日起30个交易日后的三个月内通 过集中竞价或大宗交易减持鹿得医疗1,000,000股，计划减持数量占总股本比例0.5682%。 根据鹿得医疗披露的2024年年度报告，该公司实际控制人为自然人项友亮、黄捷静、项国强。项友亮， 男，中国国籍，具有澳大利亚永久居留权；黄捷静，女，澳大利亚籍；项国强，男，中国国籍，无境外 永久居留权。朱文军为鹿得医疗董事、副总经理。 2025年6月4日，鹿得医疗发布公告称，公司于2025年6月4日收到员工持股平台上海鹿晶投资管理中心 （有限合伙）出具的《股份减持结果的告知函》。 上海鹿晶投资管理中心（有限合伙）于2025年5月30日至2025年6月4日通过集中竞价方式减持鹿得医疗 ...

Core Viewpoint - The medical device sector experienced a decline of 2.16% on August 14, with Lide Man leading the drop, while the Shanghai Composite Index fell by 0.46% and the Shenzhen Component Index decreased by 0.87% [1]. Group 1: Market Performance - The medical device sector's overall performance was negative, with a notable decline in key stocks [1]. - Lide Man's stock price fell by 11.21%, closing at 10.06, with a trading volume of 1.06 million shares [2]. - The sector saw a net outflow of 1.517 billion yuan from major funds, while retail investors contributed a net inflow of 1.269 billion yuan [2]. Group 2: Top Gainers - Botao Biological (688767) saw a significant increase of 19.99%, closing at 45.13 with a trading volume of 104,300 shares and a transaction value of 436 million yuan [1]. - Toukeng Life (300642) rose by 10.85%, closing at 19.10 with a trading volume of 310,100 shares [1]. - Jimin Health (603222) increased by 10.05%, closing at 8.10 with a trading volume of 944,800 shares [1]. Group 3: Notable Decliners - Lide Man (300289) led the decline with a drop of 11.21%, closing at 10.06 with a trading volume of 1.0605 million shares [2]. - Zhonghong Medical (300981) fell by 9.91%, closing at 16.00 with a trading volume of 261,300 shares [2]. - Haitai New Light (688677) decreased by 7.93%, closing at 45.30 with a trading volume of 49,100 shares [2].

鹿得医疗是一家专注于医疗器械研发、生产和销售的企业。公司产品涵盖多个医疗领域，主要服务于医 疗机构和终端患者。作为医疗器械板块的重要成员，其业务发展与行业整体走势密切相关。 截至2025年8月13日收盘，鹿得医疗股价报12.19元，较前一交易日下跌0.35元。当日成交量为92237手， 成交金额达1.12亿元。 风险提示：市场有风险，投资需谨慎。本文所载信息仅供参考，不构成任何投资建议。 从市场表现来看，8月13日医疗器械板块整体呈现调整态势。板块内多只个股出现不同程度下跌，其中 鹿得医疗跌幅为2.79%。当日公司股价波动区间为12.03元至12.48元，振幅达到3.59%。 来源：金融界 ...

证券代码：832278 证券简称：鹿得医疗 公告编号：2025-086 二、 本次减持计划的主要内容 | | | 计划减 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 计划减持 | 持数量 | 减持 | 减持 | | 减持价格 | 拟减持 | 拟减持 | | | 数量 | 占总股 | | | | | 股份来 | | | 称 | | | 方式 | 期间 | | 区间 | | 原因 | | | （股） | 本比例 | | | | | 源 | | | | | （%） | | | | | | | | 项国强 | 2,480,000 | 1.4091% | 集中 | 自 | 本 | 根据市场 | 上市前 | 个人资 | | | | | 竞价 | 公 | 告 | 价格 | 取得 | 金需求 | | | | | 或大 | 披 | 露 | | | | 股东名称 股东身份 持股数量 （股） 持股比例 （%） 当前持股股份来源 项国强 持股 5%以 上股东、实 际控制人、 董事 10,238,400 5.8173% 上市 ...

（文章来源：每日经济新闻） 每经AI快讯，8月13日，医疗设备板块短线走低，麦澜德跌超7%，翔宇医疗、澳华内镜、鹿得医疗、伟 思医疗等跟跌。 ...

Core Viewpoint - The medical nebulizer industry is experiencing significant growth driven by the aging population and the increasing prevalence of chronic respiratory diseases, with the market size in China projected to reach 4.281 billion yuan by 2024, reflecting an 11.4% year-on-year increase [1][14]. Industry Overview - Medical nebulizers are devices that convert liquid medication into aerosol particles for inhalation, primarily used to treat various respiratory diseases [3]. - The main types of nebulizers include compressed air nebulizers, ultrasonic nebulizers, and mesh nebulizers, each with distinct mechanisms and applications [4][5]. Market Dynamics - The market for medical nebulizers is expected to grow due to the rising number of healthcare institutions, which reached 1,093,600 in China by the end of 2024, a 2.13% increase year-on-year [12]. - The production of medical nebulizers in China is also on the rise, with an expected output of 22.37 million units in 2024, marking a 12.6% increase [18]. Competitive Landscape - The market features numerous participants, including both international brands like Omron and Philips, and domestic companies such as Yuyue Medical and Haier Medical, which are enhancing their competitiveness through R&D and quality improvements [20]. Product Segmentation - Compressed nebulizers dominate the market with a 78% share due to their efficiency, while ultrasonic nebulizers hold a smaller share of 3%, and mesh nebulizers have gained traction with a 19% market share [16]. Regulatory Environment - The Chinese government is actively promoting the development of the medical nebulizer industry through various policies aimed at enhancing innovation and regulatory frameworks [7]. Future Trends - The industry is moving towards precision medication delivery, smart nebulizers for remote monitoring, and portable, eco-friendly designs to enhance user experience [26][27][28].

Core Viewpoint - The medical device industry experienced a slight increase of 0.93% on August 8, with a net outflow of 611 million yuan in main capital, indicating a mixed performance among constituent stocks [1] Group 1: Market Performance - A total of 59 constituent stocks rose while 39 fell, reflecting a generally positive sentiment despite the capital outflow [1] - The main capital outflow was led by Anbiping with 11.75 million yuan, followed by Dongfulong with 10.71 million yuan, and Anjiasi with 9.95 million yuan [1] Group 2: Notable Stocks - Mindray Medical (code: 300760) had a latest price of 230.71 yuan with a slight decrease of 0.03% and a net inflow of 107 million yuan, accounting for 7.18% of the main capital [1] - Lepu Medical (code: 300003) saw a price of 17.27 yuan, an increase of 6.93%, with a net inflow of 107 million yuan, representing 5.73% of the main capital [1] - Meihua Medical (code: 300136) reported a price of 20.03 yuan, up by 7.17%, with a net inflow of 559.96 million yuan, which is 11.04% of the main capital [1] - Kangdelai (code: 603987) had a price of 9.23 yuan, increasing by 5.73%, with a net inflow of 485.15 million yuan, making up 12.43% of the main capital [1] - Other notable stocks include Baikang (code: 688068) with a price of 42.58 yuan and a net inflow of 394.93 million yuan, and Sainuo Medical (code: 688108) with a price of 20.44 yuan, up by 20.02%, and a net inflow of 2762.62 million yuan [1]

证券时报·数据宝统计显示，鹿得医疗所属的医药生物行业，目前整体涨幅为0.46%，行业内，目前股价 上涨的有344只，涨停的有赛诺医疗、创新医疗等5只。股价下跌的有138只，跌幅居前的有凯莱英、上 海谊众、安必平等，跌幅分别为7.72%、5.75%、4.92%。 两融数据显示，该股最新（8月7日）两融余额为918.59万元，其中，融资余额为918.59万元，近10日增 加239.05万元，环比增长35.18%。 鹿得医疗股价创出历史新高，截至10:31，该股上涨10.09%，股价报13.09元，成交量1021.02万股，成交 金额1.26亿元，换手率13.51%，该股最新A股总市值达23.04亿元，该股A股流通市值9.89亿元。 公司发布的一季报数据显示，一季度公司共实现营业收入6109.37万元，同比下降7.42%，实现净利润 633.43万元，同比增长62.89%，基本每股收益为0.0400元，加权平均净资产收益率1.57%。（数据宝） （文章来源：证券时报网） ...

证券代码：832278 证券简称：鹿得医疗 公告编号：2025-085 江苏鹿得医疗电子股份有限公司 关于减少注册资本通知债权人的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、通知债权人的原由 江苏鹿得医疗电子股份有限公司（以下简称"公司"）于 2025 年 7 月 11 日 召开公司第四届董事会第九次会议，审议通过了《关于变更回购股份用途并注 销暨减少注册资本的议案》及《关于减少注册资本、取消监事会并修订<公司章 程>的议案》，上述议案已于 2025 年 7 月 29 日经公司 2025 年第一次临时股东会 审议通过。 根据《中华人民共和国公司法》《北京证券交易所上市公司持续监管指引第 4号——股份回购》等法律、法规及规范性文件的有关规定，鉴于公司目前暂无 实施员工持股计划及股权激励的具体计划，为提升股东价值，增加每股净资产 和每股股权对应的收益权益，增强投资者对公司的投资信心，维护广大投资者 的利益，公司拟对 2022年 9月完成回购的 1,500,000股股份进行注销，将导致公 司总股 ...